[{"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-001", "question": "A 14-year-old competitive swimmer with genotype-positive, phenotype-negative catecholaminergic polymorphic ventricular tachycardia (RYR2 exon 3 p.Arg2474Ser mutation) experiences syncope during a sanctioned meet. Ambulatory monitoring shows bidirectional ventricular tachycardia at 180 bpm during exercise. Baseline QTc is 410 ms. Which long-term pharmacologic strategy is most likely to prevent arrhythmic recurrence?", "options": ["Nadolol 1 mg/kg/day with exercise restriction", "Flecainide 100 mg twice daily as monotherapy", "Nadolol 1 mg/kg/day plus flecainide 100 mg twice daily", "Verapamil 240 mg daily with ICD backup", "ICD implantation with sotalol 120 mg twice daily"], "answer": "C", "answer_index": 2, "explanation": "Specific RYR2 mutations in the channel core (exon 3) demonstrate poor response to beta-blockade alone; combination therapy with flecainide provides synergistic RyR2 stabilization by reducing calcium leak. Verapamil lacks efficacy in CPVT, and ICD shocks can trigger catecholamine surge and arrhythmic storms.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: V. Verdict: Correct best. Key stem clues: genotype-positive, phenotype-negative CPVT with exon 3 RYR2 mutation; syncope with bidirectional VT on exercise; baseline QTc normal. The item correctly identifies a specific high-risk mutation (exon 3, channel core) known in guidelines to have suboptimal response to beta-blocker monotherapy, making combination therapy (nadolol + flecainide) the most likely effective pharmacologic strategy. No logical contradictions exist. Medical accuracy is high, aligning with recent consensus on genotype-directed therapy. The only minor nuance is that 'phenotype-negative' is slightly atypical phrasing post-syncope with documented VT, but it likely indicates no baseline ECG signs. Minimal fix: Clarify 'phenotype-negative' as 'asymptomatic at rest with normal baseline ECG' to avoid ambiguity.\",\n    \"logical_false_reason\": \"T\",\n    \"logical_validity\": true,\n    \"medical_accuracy_score\":", "judge_output_valid": false, "judge_parse_error": "json decode error: Expecting value: line 5 column 30 (char 959)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-002", "question": "A 72-hour-old term neonate presents with lethargy and poor feeding. Plasma ammonia is 920 μmol/L, arterial pH 7.32, anion gap 12 mEq/L. Urine orotic acid is undetectable. Plasma amino acids show elevated glutamine with decreased citrulline and arginine. Which intervention directly addresses the primary enzymatic defect?", "options": ["Intravenous sodium phenylbutyrate 250 mg/kg", "Oral carglumic acid 100 mg/kg", "Emergent hemodialysis", "Intravenous arginine HCl 200 mg/kg", "Protein restriction to 0.5 g/kg/day"], "answer": "B", "answer_index": 1, "explanation": "Carbamoyl phosphate synthetase I deficiency is uniquely responsive to carglumic acid, which allosterically activates the defective enzyme by increasing its affinity for N-acetylglutamate. Sodium phenylbutyrate and arginine require functional CPS1 activity to excrete nitrogen and are ineffective. Hemodialysis is temporizing but not disease-specific.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: hyperammonemia, low citrulline/arginine, undetectable urine orotic acid, and elevated glutamine point to a proximal urea cycle defect (CPS1 or NAGS deficiency). The keyed answer (B, carglumic acid) is the definitive treatment for N-acetylglutamate synthase (NAGS) deficiency, not CPS1 deficiency. The rationale incorrectly states carglumic acid activates CPS1; it replaces the missing N-acetylglutamate in NAGS deficiency. For CPS1 deficiency, the primary defect is not addressed by any listed drug; arginine (D) is a standard supportive therapy to drive the downstream urea cycle, making it a more logical 'best' answer given the options, though not a direct enzyme replacement. Main logical issue: The key does not match the most defensible answer based on the pathophysiology presented. Main medical issue: The rationale contains a pathophysiological inaccuracy regarding carglumic acid's mechanism. Minimal fix: Change the rationale to correctly state carglumic acid is for NAGS deficiency, or change the vignette findings (e.g., mention NAGS deficiency) to match the key.\",\n    \"logical_false_reason\": \"K\",\n    \"logical_validity\": false,\n    \"medical_accuracy_score\":  \"2\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: hyperammonemia, low citrulline/arginine, undetectable urine orotic acid, and elevated glutamine point to a proximal urea cycle defect (CPS1 or NAGS deficiency). The keyed answer (B, carglumic acid) is the definitive treatment for N-acetylglutamate synthase (NAGS) deficiency, not CPS1 deficiency. The rationale incorrectly states carglumic acid activates CPS1; it replaces the missing N-acetylglutamate in NAGS deficiency. For CPS1 deficiency, the primary defect is not addressed by any listed drug; arginine (D) is a standard supportive therapy to drive the downstream urea cycle, making it a more logical 'best' answer given the options, though not a direct enzyme replacement. Main logical issue: The key does not match the most defensible answer based on the pathophysiology presented. Main medical issue: The rationale contains a pathophysiological inaccuracy regarding carglumic acid's mechanism. Minimal fix: Change the rationale to correctly state carglumic acid is for NAGS deficiency, or change the vignette findings (e.g., mention NAGS deficiency) to match the key.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-003", "question": "A 30-year-old diver is stung on the neck by a thumbnail-sized jellyfish off the Great Barrier Reef. Initial pain resolves, but 45 minutes later develops severe lower back pain, dyspnea, and pulmonary edema with systolic BP 190 mmHg. Which therapy specifically antagonizes the pathophysiologic cascade?", "options": ["Chironex fleckeri antivenom 20,000 units IV", "Magnesium sulfate 50 mg/kg IV bolus then infusion", "Calcium gluconate 1 g IV", "Fentanyl 100 μg IV", "Verapamil 5 mg IV"], "answer": "B", "answer_index": 1, "explanation": "Irukandji syndrome from Carukia barnesi triggers massive catecholamine release via voltage-gated sodium channel modulation; magnesium sulfate inhibits catecholamine release and reduces calcium influx at presynaptic terminals. Chironex antivenom is ineffective against Irukandji toxins, while calcium may worsen catecholamine release.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: K. Verdict on keyed answer: Miskeyed. Key stem clues: jellyfish sting off Great Barrier Reef, initial pain resolves, delayed (45 min) severe back pain, dyspnea, pulmonary edema, and severe hypertension. This classic presentation is Irukandji syndrome. The pathophysiologic cascade involves catecholamine storm. The therapy that specifically antagonizes this cascade is verapamil, a calcium channel blocker, which is a well-documented, specific treatment for Irukandji-induced hypertension and myocardial dysfunction. Magnesium sulfate, while used for some envenomations, is not the specific, first-line antagonist for Irukandji catecholamine effects in this acute, severe hypertensive setting. Main logical issue: A unique best answer (E) exists, but the provided key (B) is incorrect. Main medical accuracy issue: Magnesium is not the standard specific antagonist for this syndrome's hypertensive crisis. Minimal fix: Change the correct answer key from B to E.\",\n    \"logical_false_reason\": \"K\",\n    \"logical_validity\": false,\n    \"medical_accuracy_score\":", "judge_output_valid": false, "judge_parse_error": "json decode error: Expecting value: line 5 column 30 (char 1092)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-004", "question": "An 8-year-old boy presents with recurrent lacunar strokes, livedo racemosa, and systemic vasculitis. Biopsy shows necrotizing vasculitis without immune complex deposition. Immunoglobulins show IgM 28 mg/dL (low). Genetic testing reveals ADA2 biallelic loss-of-function mutations. Which biologic therapy directly interrupts the disease-driving signaling cascade?", "options": ["High-dose prednisone 2 mg/kg/day", "Cyclophosphamide 500 mg/m² monthly", "Etanercept 0.4 mg/kg twice weekly", "Adalimumab 20 mg every 2 weeks", "Anakinra 2 mg/kg daily"], "answer": "D", "answer_index": 3, "explanation": "Deficiency of adenosine deaminase 2 causes uncontrolled type I interferon and TNF-α signaling; TNF inhibition with adalimumab (monoclonal antibody) is superior to etanercept (soluble receptor) which can bind mutant ADA2 and paradoxically worsen inflammation. Anakinra targets IL-1 and is ineffective for DADA2.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed. The stem clearly describes deficiency of adenosine deaminase 2 (DADA2), a monogenic autoinflammatory disease. The keyed answer is adalimumab, a TNF-α inhibitor. However, the rationale provided states that etanercept can paradoxically worsen inflammation, implying it is inferior. This creates a direct contradiction: if etanercept is contraindicated, then adalimumab is the correct therapeutic choice. The item is therefore miskeyed because the correct answer (D) is not the one indicated as correct in the provided 'Correct answer key' field, which is also 'D'. The logical failure is that the key and the explanation are inconsistent. The medical content is accurate regarding DADA2 pathophysiology and the superiority of monoclonal anti-TNF over etanercept. Minimal fix: Correct the key to match the intended correct answer, which is D (Adalimumab), and ensure the 'Correct answer key' field reflects this.\",\n    \"logical_false_reason\": \"K\",\n    \"logical_validity\": false,\n    \"medical_accuracy_score\":", "judge_output_valid": false, "judge_parse_error": "json decode error: Expecting value: line 5 column 30 (char 1073)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-005", "question": "A 23-year-old graduate student has persistent fasting glucose 108-115 mg/dL and HbA1c 6.1-6.3% discovered on routine screening. BMI is 22 kg/m², islet autoantibodies are negative, and both parents have mild hyperglycemia. A heterozygous GCK pathogenic variant is identified. Which management strategy is supported by longitudinal natural history data?", "options": ["Metformin 500 mg twice daily", "Glipizide 5 mg daily", "Sitagliptin 100 mg daily", "No pharmacologic therapy", "Basal insulin 0.2 units/kg"], "answer": "D", "answer_index": 3, "explanation": "Glucokinase MODY resets the glucose threshold to ~140 mg/dL but maintains tight regulation around this setpoint; large cohort studies show no increased microvascular or macrovascular complications, making pharmacotherapy unnecessary. Sulfonylureas are ineffective as they don't correct the underlying glucokinase defect.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: young adult, mild persistent fasting hyperglycemia (108-115 mg/dL), mildly elevated HbA1c (6.1-6.3%), normal BMI, negative autoantibodies, family history of mild hyperglycemia, and identification of a heterozygous GCK (glucokinase) pathogenic variant. This profile is classic for GCK-MODY (MODY 2). The logical flow is sound; the question asks for the management strategy supported by longitudinal natural history data. The keyed answer (D, no pharmacologic therapy) is strongly supported by the established natural history of GCK-MODY, which demonstrates a stable, mild hyperglycemia without increased risk of diabetic complications, making pharmacologic treatment unnecessary and ineffective. The alternatives are all pharmacologic interventions, which are not indicated. No contradictions or underspecification exist. The medical content is accurate. Minimal fix: None required; the item is valid and accurate as written.\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\":  \t\n  \"5\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: young adult, mild persistent fasting hyperglycemia (108-115 mg/dL), mildly elevated HbA1c (6.1-6.3%), normal BMI, negative autoantibodies, family history of mild hyperglycemia, and identification of a heterozygous GCK (glucokinase) pathogenic variant. This profile is classic for GCK-MODY (MODY 2). The logical flow is sound; the question asks for the management strategy supported by longitudinal natural history data. The keyed answer (D, no pharmacologic therapy) is strongly supported by the established natural history of GCK-MODY, which demonstrates a stable, mild hyperglycemia without increased risk of diabetic complications, making pharmacologic treatment unnecessary and ineffective. The alternatives are all pharmacologic interventions, which are not indicated. No contradictions or underspecification exist. The medical content is accurate. Minimal fix: None required; the item is valid and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-006", "question": "A 65-year-old man with heart failure presents with LV wall thickness 15 mm, global longitudinal strain -8%, and apical sparing ratio 2.5. Serum lambda light chains are 180 mg/L with free light chain difference 150 mg/L. Which regimen has demonstrated survival benefit in stage IIIb AL amyloidosis with cardiac involvement?", "options": ["Bortezomib-cyclophosphamide-dexamethasone", "Daratumumab-bortezomib-dexamethasone", "Orthotopic heart transplant", "Doxycycline 100 mg twice daily", "Tafamidis 61 mg daily"], "answer": "B", "answer_index": 1, "explanation": "The ANDROMEDA trial demonstrated that daratumumab-based regimens achieve rapid and deep hematologic responses, translating to improved cardiac function and survival in high-risk AL amyloidosis. Tafamidis is indicated for transthyretin, not light-chain amyloidosis. Doxycycline remains investigational.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: AL amyloidosis (elevated lambda free light chains, free light chain difference) with severe cardiac involvement (LV wall thickness 15 mm, reduced global longitudinal strain -8%, apical sparing ratio 2.5) defines stage IIIb disease. The question asks for a regimen with demonstrated survival benefit. Main logical issue: None; the stem provides sufficient diagnostic and staging criteria. Main medical accuracy issue: None; the key aligns with current evidence. Minimal fix: None required; the item is clear and accurate. The ANDROMEDA trial supports daratumumab-bortezomib-dexamethasone (D-Vd) for this high-risk population, while other options are for different amyloid types, are not first-line systemic therapy, or lack the same survival evidence.\",\n    \"logical_false_reason\": \"T\",\n    \"logical_validity\": true,\n    \"medical_accuracy_score\":", "judge_output_valid": false, "judge_parse_error": "json decode error: Expecting value: line 5 column 30 (char 938)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-007", "question": "A 4-day-old neonate exhibits burst-suppression pattern on EEG and multifocal seizures refractory to phenobarbital 40 mg/kg and levetiracetam 50 mg/kg. Targeted epilepsy panel reveals a de novo KCNQ2 gain-of-function mutation. Which anticonvulsant mechanism is most likely to achieve seizure freedom?", "options": ["GABAergic enhancement with clobazam", "Sodium channel blockade with phenytoin", "Sodium channel blockade with carbamazepine", "Synaptic vesicle modulation with brivaracetam", "Ketogenic diet 4:1 ratio"], "answer": "C", "answer_index": 2, "explanation": "Despite KCNQ2 encoding a potassium channel, gain-of-function mutations cause hyperexcitability that paradoxically responds best to sodium channel blockers like carbamazepine, which reduce overall neuronal firing. Phenobarbital and levetiracetam are often ineffective in this channelopathy.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed. The stem describes a neonate with KCNQ2 gain-of-function mutation causing refractory seizures. The keyed answer (C, carbamazepine) is not the best-supported choice. For KCNQ2-related disorders, gain-of-function mutations cause a distinct, self-limited neonatal epilepsy that is typically exquisitely responsive to sodium channel blockers, but carbamazepine and phenytoin (B, C) are both sodium channel blockers. The vignette provides no detail to discriminate between these two options, making them equally plausible and creating a 'multiple defensible' (M) scenario. The medical accuracy is sound regarding the general drug class, but the item is logically flawed due to the indistinguishable options. Minimal fix: Remove one of the redundant sodium channel blockers (e.g., change option B or C to a mechanistically distinct, incorrect choice) to force a unique best answer.\",\n    \"logical_false_reason\": \"M\",\n    \"logical_validity\": false,\n    \"medical_accuracy_score\":  \"4\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed. The stem describes a neonate with KCNQ2 gain-of-function mutation causing refractory seizures. The keyed answer (C, carbamazepine) is not the best-supported choice. For KCNQ2-related disorders, gain-of-function mutations cause a distinct, self-limited neonatal epilepsy that is typically exquisitely responsive to sodium channel blockers, but carbamazepine and phenytoin (B, C) are both sodium channel blockers. The vignette provides no detail to discriminate between these two options, making them equally plausible and creating a 'multiple defensible' (M) scenario. The medical accuracy is sound regarding the general drug class, but the item is logically flawed due to the indistinguishable options. Minimal fix: Remove one of the redundant sodium channel blockers (e.g., change option B or C to a mechanistically distinct, incorrect choice) to force a unique best answer.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-008", "question": "A 36-year-old woman with migraine with aura develops acute right hemiparesis (NIHSS 8) and arrives within 90 minutes of symptom onset. MRI shows anterior temporal lobe T2 hyperintensities and external capsule involvement. Which intervention is contraindicated due to disease-specific pathophysiology?", "options": ["IV tPA 0.9 mg/kg", "Aspirin 325 mg", "Clopidogrel 600 mg", "Supportive care in stroke unit", "Mechanical thrombectomy"], "answer": "A", "answer_index": 0, "explanation": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) involves fragile small vessels with thickened walls and perivascular deposits; thrombolysis carries excessive hemorrhagic risk due to vessel fragility. Mechanical thrombectomy is also contraindicated for lacunar strokes typical in CADASIL.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: acute hemiparesis, NIHSS 8, presentation <90 minutes, MRI findings of anterior temporal lobe and external capsule T2 hyperintensities are classic for CADASIL. The question asks for an intervention contraindicated due to disease-specific pathophysiology. The keyed answer (A, IV tPA) is not definitively contraindicated in CADASIL; major guidelines do not list it as an absolute contraindication, and the risk-benefit in an acute disabling stroke within the window favors tPA. The rationale incorrectly states thrombolysis carries 'excessive hemorrhagic risk,' which is not a consensus contraindication. Option E (Mechanical thrombectomy) is a more defensible 'contraindicated' answer for this clinical picture, as the MRI pattern suggests small vessel (lacunar) disease, not a large vessel occlusion amenable to thrombectomy. Main logical issue: The key does not match the most defensible best answer. Main medical accuracy issue: Overstates the contraindication to tPA in CADASIL. Minimal fix: Change the key to E and adjust the rationale to focus on the inappropriateness of thrombectomy for lacunar strokes.\",\n    \"logical_false_reason\": \"K\",\n    \"logical_validity\": false,\n    \"medical_accuracy_score\":", "judge_output_valid": false, "judge_parse_error": "json decode error: Expecting value: line 5 column 30 (char 1290)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-009", "question": "A 29-year-old man with lifelong recurrent fevers (>38.5°C), severe abdominal pain, myalgia, and periorbital edema has an identified TNFRSF1A cysteine mutation. Which biologic therapy is preferred over etanercept due to mechanistic considerations?", "options": ["Colchicine 0.6 mg twice daily", "Etanercept 50 mg weekly", "Anakinra 100 mg daily", "Canakinumab 150 mg every 8 weeks", "Tocilizumab 8 mg/kg monthly"], "answer": "C", "answer_index": 2, "explanation": "Tumor necrosis factor receptor-associated periodic syndrome involves misfolded TNFRSF1A that can bind etanercept, forming complexes that prolong inflammation. IL-1 receptor antagonism with anakinra bypasses this mechanism and is first-line therapy. Colchicine is ineffective for TRAPS.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: lifelong recurrent fevers, abdominal pain, myalgia, periorbital edema, and a confirmed TNFRSF1A cysteine mutation establish the diagnosis of TNF receptor-associated periodic syndrome (TRAPS). The question explicitly asks for a biologic therapy preferred over etanercept due to mechanistic considerations. The provided rationale correctly states that etanercept can bind the mutant receptor and potentially prolong inflammation, making IL-1 inhibition (anakinra) the preferred biologic. The other options are incorrect: colchicine is not a biologic and is ineffective; etanercept is the agent to be avoided; canakinumab and tocilizumab are biologics but target IL-1β and IL-6, respectively, and are not first-line for TRAPS. The item is logically valid and medically accurate. Minimal fix: None required; the item is clear and defensible.\",\n    \"logical_false_reason\": \"T\",\n    \"logical_validity\": true,\n    \"medical_accuracy_score\":", "judge_output_valid": false, "judge_parse_error": "json decode error: Expecting value: line 5 column 30 (char 1025)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-010", "question": "A 21-year-old woman with hypertension and a 4-cm adrenal mass has plasma normetanephrine 8.2 nmol/L (ref <0.6). Genetic testing reveals a pathogenic SDHB variant. Which preoperative preparation strategy addresses the unique catecholamine synthesis profile of SDH-related tumors?", "options": ["Phenoxybenzamine 10 mg twice daily for 14 days", "Metyrosine 250 mg four times daily for 7 days", "Phenoxybenzamine plus metyrosine for 10-14 days", "Immediate laparoscopic adrenalectomy", "Amlodipine 10 mg daily only"], "answer": "C", "answer_index": 2, "explanation": "SDH-related pheochromocytomas/paragangliomas exhibit high tyrosine hydroxylase activity and catecholamine synthesis rates, requiring both irreversible alpha-blockade (phenoxybenzamine) and catecholamine synthesis inhibition (metyrosine) for adequate preoperative preparation. Alpha-blockade alone may be insufficient for the catecholamine surge.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: V. Verdict: Correct best. The question asks for the preoperative strategy for an SDHB-related pheochromocytoma/paraganglioma (PCC/PGL) given high normetanephrine. Key stem clues are the confirmed SDHB mutation and the biochemical evidence of catecholamine excess, which in SDHx tumors is associated with high synthesis rates. The provided rationale correctly states that combined alpha-blockade and catecholamine synthesis inhibition is the recommended approach for these high-risk tumors, making option C the single best answer. The item is medically accurate and logically valid. Alternatives are inferior: A (alpha-blockade alone) may be insufficient; B (metyrosine alone) lacks alpha-blockade; D (immediate surgery) is dangerous without preparation; E (amlodipine) is inadequate. No missing details or contradictions. A minimal fix is not needed, but the stem could explicitly state 'pheochromocytoma' for absolute clarity, though it is strongly implied.\",\n    \"logical_false_reason\": \"T\",\n    \"logical_validity\": true,\n    \"medical_accuracy_score\":", "judge_output_valid": false, "judge_parse_error": "json decode error: Expecting value: line 5 column 30 (char 1088)"}]